| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00448266 Details | 2021-01-22 Interventional | 2/3 | 12 | Carboplatin Cyclophosphamid… Thiotepa Breast Neoplasm… Breast Cancer | Activation of a similar multicenter study for same population - | |||
| NCT02523768 2009-018189-36 Details | 2021-01-20 Interventional | 4 | 117 | Basiliximab Glomerulonephri… Glomerulonephri… Recurrence IgAN | Difficulties for recruting patients - | |||
| NCT00524030 Details | 2021-01-20 Interventional | 3 | 161 | Pregabalin Epilepsies, Par… Epilepsy Seizures | See termination reason in detailed description. External Data Monitoring Committee (DMC) determined study met criteria to stop early for positive efficacy. Exit rate was the basis for primary analysis and is what is reported here. | |||
| NCT04131556 Details | 2021-01-19 Interventional | 1 | 20 | Maribavir Healthy Volunte… | The study was stopped because based on the planned interim analysis of the data of Part 1,
palatability of both pediatric formulations was not acceptable. Sponsor terminated this study based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable. | |||
| NCT03262038 Details | 2021-01-19 Interventional | 4 | 46 | Ondansetron Pruritus Vomiting Nausea/Vomiting | Interim analysis showed no difference between groups - | |||
| NCT01694381 2012-002225-30 Details | 2021-01-19 Interventional | 1 | 8 | Complement C1 I… Ischemic Stroke Acute Ischemic … | - - | |||
| NCT01546857 Details | 2021-01-19 Interventional | 4 | 34 | Gabapentin Osteoarthritis Pain, Postopera… Degenerative Ar… | No longer able to recruit subjects due to unavailability of orthopedic surgeon. - | |||
| NCT04364009 2020-001734-36 Details | 2021-01-15 Interventional | 3 | 71 | Interleukin 1 R… COVID-19 Signs and Sympt… ANAKINRA Treatm… COVID-19 Infect… Optimized Stand… | Efficiency and safety reasons - | |||
| NCT01984268 Details | 2021-01-15 Interventional | 2 | 15 | Adrenocorticotr… Arthritis Arthritis, Rheu… Rheumatoid Arth… | - - | |||
| NCT03519061 Details | 2021-01-14 Interventional | 2/3 | 0 | Budesonide Chronic Disease Rhinosinusitis Sinusitis Chronic Sinus C… Chronic Sinus I… Chronic Sinusit… Chronic Sinusit… | Unable to obtain FDA exemption - | |||
| NCT03119701 2014-000899-25 Details | 2021-01-14 Interventional | 2 | 40 | Interferon beta… Interferon-beta Interferons Multiple Organ … Multi Organ Fai… Preventive Medi… | IDMC recommendation. Unexpectedly high use of concomitant corticosteroid treatment. The study was prematurely stopped and due to this the planned statistical power for the primary comparisons was not reached. | |||
| NCT02992340 Details | 2021-01-14 Interventional | 1/2 | - | Gemcitabine Biliary Tract N… Biliary Tract C… | Sponsor decided to terminate the study and not proceed to Phase 2. - | |||
| NCT02587962 Details | 2021-01-14 Interventional | 1/2 | 34 | Pembrolizumab Neoplasms Solid Tumors | Based on a futility analysis, the data monitoring committee recommended to stop enrollment. The dose escalation (Phase 1) part was analyzed per the protocol. Based on data from the interim analysis of the colorectal cancer cohort (dose expansion [Phase 2] part), the study was closed early due to futility on recommendation by the data monitoring committee (DMC). | |||
| NCT02547116 Details | 2021-01-14 Interventional | 4 | 0 | Rifampin Cystic Fibrosis Fibrosis MRSA | Administrative delay - | |||
| NCT02956122 Details | 2021-01-13 Interventional | 2/3 | 1 | Alpha 1-Antitry… Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Protease Inhibi… Graft vs Host D… Graft Versus Ho… | The decision to discontinue the study was based on business reasons. - | |||
| NCT00133679 Details | 2021-01-13 Interventional | 4 | 9 | Sildenafil Citr… Hernia Hernia, Diaphra… Hernias, Diaphr… Hypertension, P… Hypoplasia, Pul… | Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with
possibility of placebo beyond 6 weeks of age on study protocol - | |||
| NCT04131322 Details | 2021-01-12 Interventional | 4 | 24 | Adalimumab Pharmaceutical … Crohn Disease Ulcerative Coli… | Sponsor cancellation - | |||
| NCT02540356 2015-003492-29 Details | 2021-01-12 Interventional | 1/2 | 2 | Antibodies Immunoglobulins Ascites Carcinoma, Ovar… Ovarian Neoplas… Refractory Ovar… | - Study was terminated early with only 1 subject having been dosed. Therefore no statistical analysis was performed on the outcome measures. Only descriptive data for one subject are available. | |||
| NCT03412734 Details | 2021-01-11 Interventional | 4 | [1 Refs] | 94 | Chlorhexidine Hysterectomy | The institutional review board recommended the study stop enrollment prior to achieving its
initial sample size for patient safety. - | ||
| NCT04002635 Details | 2021-01-08 Interventional | 4 | 0 | Estradiol Estradiol 17 be… Estradiol 3-ben… Letrozole Polyestradiol p… Progesterone Infertility Infertility, Fe… Polycystic Ovar… Syndrome IVF Ovulation Disor… | Practical issues - |